Greenwich LifeSciences, Inc.
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$19.4M
- Total assets
- $6.2M
- Market cap
- $326.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $19.4M
- Operating income
- -$19.4M
- Net income
- -$19.4M
- EPS (basic)
- $-1.43
- EPS (diluted)
- $-1.43
Balance sheet
- Total assets
- $6.2M
- Current assets
- $6.2M
- Total liabilities
- $5.8M
- Current liabilities
- $5.8M
- Shareholders’ equity
- $353.2K
Cash flow
- Financing cash flow
- $12.0M
- Net cash flow
- $12.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $326.6M
- EPS (diluted)
- $-1.43
- Shares outstanding
- 15.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 25, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $19.4M.
- Trading 35% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Greenwich LifeSciences, Inc..
Write a review
News about Greenwich LifeSciences, Inc.
News & sentiment via Polygon.io
